Skip to main content
Erschienen in: International Journal of Hematology 4/2010

01.05.2010 | Case Report

A case of HIV-associated lymphoproliferative disease that was successfully treated with highly active antiretroviral therapy

verfasst von: Haruyuki Fujita, Momoko Nishikori, Akifumi Takaori-Kondo, Noriyoshi Yoshinaga, Yoshiaki Ohara, Takayuki Ishikawa, Hironori Haga, Takashi Uchiyama

Erschienen in: International Journal of Hematology | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

We report a case of a 41-year-old male with human immunodeficiency virus (HIV)-associated lymphoproliferative disease (LPD) who was successfully treated with highly active antiretroviral therapy (HAART). He presented with epigastralgia, and an upper endoscopic examination revealed submucosal tumors and ulcerations in his stomach. Histopathologic examination of a biopsy specimen resulted in a diagnosis of diffuse large B-cell lymphoma. He also showed systemic lymphadenopathy; whereas, a concurrent inguinal lymph node biopsy produced a diagnosis of follicular hyperplasia. He was treated with CHOP chemotherapy but the response was poor. He demonstrated several immunological abnormalities, such as eosinophilia and bone marrow insufficiency, and was suspected to be in an immunocompromised state. He was examined for HIV infection and turned out to be positive. The gastric and inguinal lymph node specimens were re-evaluated and diagnoses of HIV-LPD and HIV lymphadenitis were made, respectively. He was treated with HAART and achieved complete remission and has remained tumor-free for 20 months. To the best of our knowledge, there is no previous report in which HIV-LPD was successfully treated with antiretroviral therapy alone. It is assumed that HAART resulted in the restoration of anti-tumor immunity in this case, which led to the eradication of LPD cells.
Literatur
1.
Zurück zum Zitat Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC press; 2008. p. 340–342. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC press; 2008. p. 340–342.
2.
Zurück zum Zitat Rezk SA, Weiss LM. Epstein-Barr virus-associated lymphoproliferative disorders. Hum Pathol. 2007;38:1293–304.CrossRefPubMed Rezk SA, Weiss LM. Epstein-Barr virus-associated lymphoproliferative disorders. Hum Pathol. 2007;38:1293–304.CrossRefPubMed
3.
Zurück zum Zitat Pinkerton CR, Hann I, Weston CL, Mapp T, Wotherspoon A, Hobson R, et al. Immunodeficiency-related lymphoproliferative disorders: prospective data from the United Kingdom Children’s Cancer Study Group Registry. Br J Haematol. 2002;118:456–61.CrossRefPubMed Pinkerton CR, Hann I, Weston CL, Mapp T, Wotherspoon A, Hobson R, et al. Immunodeficiency-related lymphoproliferative disorders: prospective data from the United Kingdom Children’s Cancer Study Group Registry. Br J Haematol. 2002;118:456–61.CrossRefPubMed
4.
Zurück zum Zitat van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17:2257–317.CrossRefPubMed van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17:2257–317.CrossRefPubMed
5.
Zurück zum Zitat Wenig BM, Thompson LD, Frankel SS, Burke AP, Abbondanzo SL, Sesterhenn I, et al. Lymphoid changes of the nasopharyngeal and palatine tonsils that are indicative of human immunodeficiency virus infection. A clinicopathologic study of 12 cases. Am J Surg Pathol. 1996;20:572–87.CrossRefPubMed Wenig BM, Thompson LD, Frankel SS, Burke AP, Abbondanzo SL, Sesterhenn I, et al. Lymphoid changes of the nasopharyngeal and palatine tonsils that are indicative of human immunodeficiency virus infection. A clinicopathologic study of 12 cases. Am J Surg Pathol. 1996;20:572–87.CrossRefPubMed
6.
Zurück zum Zitat Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol. 1997;14:8–14.PubMed Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol. 1997;14:8–14.PubMed
7.
Zurück zum Zitat Tao J, Valderrama E. Epstein–Barr virus-associated polymorphic B-cell lymphoproliferative disorders in the lungs of children with AIDS: a report of two cases. Am J Surg Pathol. 1999;23:560–6.CrossRefPubMed Tao J, Valderrama E. Epstein–Barr virus-associated polymorphic B-cell lymphoproliferative disorders in the lungs of children with AIDS: a report of two cases. Am J Surg Pathol. 1999;23:560–6.CrossRefPubMed
8.
Zurück zum Zitat Martin A, Flaman JM, Frebourg T, Davi F, El Mansouri S, Amouroux J, et al. Functional analysis of the p53 protein in AIDS-related non-Hodgkin’s lymphomas and polymorphic lymphoproliferations. Br J Haematol. 1998;101:311–7.CrossRefPubMed Martin A, Flaman JM, Frebourg T, Davi F, El Mansouri S, Amouroux J, et al. Functional analysis of the p53 protein in AIDS-related non-Hodgkin’s lymphomas and polymorphic lymphoproliferations. Br J Haematol. 1998;101:311–7.CrossRefPubMed
9.
Zurück zum Zitat Oyama T, Yamamoto K, Asano N, Oshiro A, Suzuki R, Kagami Y, et al. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res. 2007;13:5124–32.CrossRefPubMed Oyama T, Yamamoto K, Asano N, Oshiro A, Suzuki R, Kagami Y, et al. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res. 2007;13:5124–32.CrossRefPubMed
10.
Zurück zum Zitat Pantaleo G, Graziosi C, Fauci AS. New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med. 1993;328:327–35.CrossRefPubMed Pantaleo G, Graziosi C, Fauci AS. New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med. 1993;328:327–35.CrossRefPubMed
11.
Zurück zum Zitat Ioachim HL, Cronin W, Roy M, Maya M. Persistent lymphadenopathies in people at high risk for HIV infection. Clinicopathologic correlations and long-term follow-up in 79 cases. Am J Clin Pathol. 1990;93:208–18.PubMed Ioachim HL, Cronin W, Roy M, Maya M. Persistent lymphadenopathies in people at high risk for HIV infection. Clinicopathologic correlations and long-term follow-up in 79 cases. Am J Clin Pathol. 1990;93:208–18.PubMed
12.
Zurück zum Zitat Nador RG, Chadburn A, Gundappa G, Cesarman E, Said JW, Knowles DM. Human immunodeficiency virus (HIV)-associated polymorphic lymphoproliferative disorders. Am J Surg Pathol. 2003;27:293–302.CrossRefPubMed Nador RG, Chadburn A, Gundappa G, Cesarman E, Said JW, Knowles DM. Human immunodeficiency virus (HIV)-associated polymorphic lymphoproliferative disorders. Am J Surg Pathol. 2003;27:293–302.CrossRefPubMed
13.
Zurück zum Zitat Wang X, Nathan S, Catchatourian R, Richter H 3rd, Kovarik P. Polymorphic lymphoid proliferation presenting as ileocecal intussusception. Ann Hematol. 2007;86:453–4.CrossRefPubMed Wang X, Nathan S, Catchatourian R, Richter H 3rd, Kovarik P. Polymorphic lymphoid proliferation presenting as ileocecal intussusception. Ann Hematol. 2007;86:453–4.CrossRefPubMed
14.
Zurück zum Zitat Spina M, Jaeger U, Sparano JA, Talamini R, Simonelli C, Michieli M, et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood. 2005;105:1891–7.CrossRefPubMed Spina M, Jaeger U, Sparano JA, Talamini R, Simonelli C, Michieli M, et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood. 2005;105:1891–7.CrossRefPubMed
15.
Zurück zum Zitat Boue F, Gabarre J, Gisselbrecht C, Reynes J, Cheret A, Bonnet F, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin’s lymphoma. J Clin Oncol. 2006;24:4123–8.CrossRefPubMed Boue F, Gabarre J, Gisselbrecht C, Reynes J, Cheret A, Bonnet F, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin’s lymphoma. J Clin Oncol. 2006;24:4123–8.CrossRefPubMed
16.
Zurück zum Zitat Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005;106:1538–43.CrossRefPubMed Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005;106:1538–43.CrossRefPubMed
17.
Zurück zum Zitat Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131:59–68.CrossRefPubMed Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131:59–68.CrossRefPubMed
18.
Zurück zum Zitat Hoffmann C, Wolf E, Fatkenheuer G, Buhk T, Stoehr A, Plettenberg A, et al. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. Aids. 2003;17:1521–9.CrossRefPubMed Hoffmann C, Wolf E, Fatkenheuer G, Buhk T, Stoehr A, Plettenberg A, et al. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. Aids. 2003;17:1521–9.CrossRefPubMed
19.
Zurück zum Zitat Matthews GV, Bower M, Mandalia S, Powles T, Nelson MR, Gazzard BG. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood. 2000;96:2730–4.PubMed Matthews GV, Bower M, Mandalia S, Powles T, Nelson MR, Gazzard BG. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood. 2000;96:2730–4.PubMed
20.
Zurück zum Zitat Ribera JM, Oriol A, Morgades M, Gonzalez-Barca E, Miralles P, Lopez-Guillermo A, et al. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol. 2008;140:411–9.CrossRefPubMed Ribera JM, Oriol A, Morgades M, Gonzalez-Barca E, Miralles P, Lopez-Guillermo A, et al. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol. 2008;140:411–9.CrossRefPubMed
21.
Zurück zum Zitat Monini P, Sgadari C, Toschi E, Barillari G, Ensoli B. Antitumour effects of antiretroviral therapy. Nat Rev Cancer. 2004;4:861–75.CrossRefPubMed Monini P, Sgadari C, Toschi E, Barillari G, Ensoli B. Antitumour effects of antiretroviral therapy. Nat Rev Cancer. 2004;4:861–75.CrossRefPubMed
22.
Zurück zum Zitat Bower M, McCall-Peat N, Ryan N, Davies L, Young AM, Gupta S, et al. Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood. 2004;104:2943–6.CrossRefPubMed Bower M, McCall-Peat N, Ryan N, Davies L, Young AM, Gupta S, et al. Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood. 2004;104:2943–6.CrossRefPubMed
Metadaten
Titel
A case of HIV-associated lymphoproliferative disease that was successfully treated with highly active antiretroviral therapy
verfasst von
Haruyuki Fujita
Momoko Nishikori
Akifumi Takaori-Kondo
Noriyoshi Yoshinaga
Yoshiaki Ohara
Takayuki Ishikawa
Hironori Haga
Takashi Uchiyama
Publikationsdatum
01.05.2010
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 4/2010
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-010-0542-8

Weitere Artikel der Ausgabe 4/2010

International Journal of Hematology 4/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.